Haemophilus influenzae lipopolysaccharide inner-core oligosaccharide epitopes as vaccines for the prevention of Haemophilus influenzae infections

US7364739B2 · kind B2 · utility

Assignees

• National Research Council of Canada · CA
• The Chancellor, Masters and Scholars of the University of Oxford · GB
• Elke K. H. Schweda · SE
• Martin M{dot over (a)}nsson · SE

Inventors

• James Clare Richards · Ottawa, CA
• Andrew Cox · Ottawa, CA
• Richard Edward Moxon · Felton, GB
• Derek Hood · Felton, GB
• Elke K. H. Schweda · Nacka, SE
• Martin Mansson · Oslo, NO

Key dates

• Filing date: Aug 27, 2001
• Grant date: Apr 29, 2008
• Expiry date: Jul 20, 2022

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C08B37/00
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

The present invention relates to a lipopolysaccharide moiety comprising a conserved triheptosyl inner-core moiety of lipopolysaccharide substantially free of variable outer core oligosaccharide chain extension, and to vaccines obtaines therefrom which are cross-reactive for Haemophilus influenzae strains. The invention also relates to defined mutations in the biosynthetic machinery for lipopolysaccharide (LPS;) expression in Haemophilus influenzae useful to obtain the abovementioned moiety. The invention also relates to using conjugates of the LPS from the mutant strains so obtained to elicit a heterologous immune response against a wide range of disease-causing H. influenzae strains. More specifically, the invention relates to vaccines for prevention of bacterial infections comprising core lipopolysaccharide of Haemophilus influenzae.